FINVESTEDGE

v   Going by its 9MFY20 results, Technocraft Industries (India) is likely to notch an EPS of Rs.60 for FY20. Expect a smart jump in its share price. v   Nagpur-based Dassault Reliance Aerostructure (DRA) has started manufacturing components for Rafale fighter planes. A positive for Reliance Infrastructure which holds substantial stake in DRA. Accumulate. v   Despite the poor results, ONGC remains a good investment bet for the long term. Its falling share price provides an opportunity to accumulate. v   Atul Auto is set to double its production capacity. Its Q3 results were fairly strong despite the slowdown in the auto industry. Accumulate. v   Nelco launched aero in-flight communication services in India. A big positive for the company. Buy for the long term. v   The cement boom has begun. A good time to buy J.K. Cement which posted fantastic Q3 results. v   Vodafone Idea has shown its intent to pay its AGR dues to the Department of Telecom, which means i

Objects of the SBI Card IPO: a) The Offer for Sale: The object of the Offer for Sale is to allow the Selling Shareholders to sell an aggregate value up to Rs.8000 Crores of shares held by them.   b) Fresh Issue( 500 Crores )  The net proceeds of the Fresh Issue are proposed to be utilized for augmenting the capital base to meet the future capital requirements. Overview of SBI Card (a) They are the second-largest credit card issuer in India, with an  18.0%  market share of the Indian credit card market in terms of the number of credit cards outstanding as of September 30, 2019. SBI Card is a subsidiary of State Bank of India. (b)  They offer an extensive credit card portfolio to individual cardholders and corporate clients which includes lifestyle, rewards, travel and fuel, shopping, banking partnership cards and corporate cards covering all major cardholder segments in terms of income profiles and lifestyles. (c)  SBI Card has a broad credit card portfolio

Vinati Organics Ltd Vinati Organics is engaged in manufacturing of speciality organic intermediates and monomers. ·          The Company is virtually debt free. ·          It has good consistent profit growth of 27.41% over 5 years. ·          It has a good return on equity (ROE) track record: 3 Years ROE 24.95% Market Cap: 10,063 Cr. Current Price: 980 52 weeks High / Low : 1255.51 / 692.58 Book Value: 116.78 Stock P/E: 29.45 Dividend Yield: 0.36 % ROCE: 45.83 % ROE: 30.60 % Sales Growth (3Yrs): 20.65 % Face Value: 2.00 10 Year Op Cash to Earnings Ratio: 0.94 Return on equity: 30.60 % Return on capital employed: 45.83 % Return on assets: 30.19 % Profit growth: 62.31 % Sales growth: 25.22 % Dividend Payout Ratio: 12.74 % Unpledged promoter holding: 74.01 % PEG Ratio: 1.21 5 Yr Op Cash to Earnings Ratio: 0.92 Debt to equity: 0.00 Debt To Profit: 0.00 Interest Coverage Ratio: 420.66 Average return on

v   Strides Pharma Science plans to acquire 18 new ANDAs from Pharmaceutics International Inc, which will significantly expand its fast-growing niche offerings. A big buy! v   Going by its strong Q3 results, Apex Frozen Food is likely to post a robust FY20 performance. Its newly commissioned facilities will boost its performance further. Accumulate. v   Britannia Industries posted 23% higher PAT for Q3 on the back of cost efficiencies. It has also cut trade inventory due to the slowdown. This evergreen FMCG share deserves a place in every portfolio. v   Symphony posted an EPS of Rs.8 for Q3FY20 v/s Rs.6 in Q3FY19. Its 9MFY20 profit has already crossed the FY19 profit. Its future looks bright. Accumulate. v   Alkem Laboratories’ Q3 profit nearly doubled to Rs.390 crore. With a hefty dividend of 1100%, this share merits a buy. Accumulate on dips. v   Yet another good quarter for UPL with its highest-ever quarterly profit and an EPS of Rs.9 v/s Rs.6 last year. B